STATUS OF BROMETHALIN OUTSIDE THE UNITED STATES by Spaulding, S. R. & Spannring, H.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
Proceedings of the Thirteenth Vertebrate Pest 
Conference (1988) 
Vertebrate Pest Conference Proceedings 
collection 
March 1988 
STATUS OF BROMETHALIN OUTSIDE THE UNITED STATES 
S. R. Spaulding 
Ciba-Geigy Animal Health/Hygiene, Basel, Switzerland 
H. Spannring 
Ciba-Geigy Agricultural Research Centre, St. Aubin, Switzerland 
Follow this and additional works at: https://digitalcommons.unl.edu/vpcthirteen 
 Part of the Environmental Health and Protection Commons 
Spaulding, S. R. and Spannring, H., "STATUS OF BROMETHALIN OUTSIDE THE UNITED STATES " (1988). 
Proceedings of the Thirteenth Vertebrate Pest Conference (1988). 14. 
https://digitalcommons.unl.edu/vpcthirteen/14 
This Article is brought to you for free and open access by the Vertebrate Pest Conference Proceedings collection at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Proceedings of the 
Thirteenth Vertebrate Pest Conference (1988) by an authorized administrator of DigitalCommons@University of 
Nebraska - Lincoln. 
STATUS OF BROMETHALIN OUTSIDE THE UNITED STATES
S.R. SPAULDING,  Ciba-Geigy Animal Health/Hygiene, CH-4002 Basel, Switzerland. 
H. SPANNRING, Ciba-Geigy Agricultural Research Centre, St. Aubin, Switzerland.
ABSTRACT: Bromethalin has been extensively researched over the past decade in the United States, Switzerland, England, 
Denmark, and France. United States EPA registrations were received in 1982 and commercial pelleted formulations 
containing 0.01% bromethalin were developed and introduced in the USA by Ralston Purina (ASSAULT1*) in 1985 and 
Velsicol (VENGEANCE1*) in 1986. Ciba-Geigy is currently developing new formulations under the tradename DORATIDR 
for use outside the United States. Bromethalin acute toxicity and 14-day subchronic studies are reviewed and data from 
recently completed 90-day subchronic studies required for registration outside the US are presented. Pharmacodynamic 
studies have shown that bromethalin acts as an uncoupler of oxidative phosphorylation, thus interrupting the vital production
of ATP necessary to maintain essential metabolic functions. Laboratory and field trial data are presented from Switzerland, 
France, England, and Denmark that indicate the effectiveness of new bromethalin formulations against anticoagulant 
resistant and susceptible rodents. A comparative rodenticide pen testing system is described from which test results 
confirm bromethalin's quick action and feed consumption efficiency when compared to second-generation 
anticoagulants.
Proc. Vertebr. Pest Conf. (A.C. Ciabb and R.E. Marsh, Eds.), 
Printed at Univ. of Calif., Davis. 13:64-69, 1988
INTRODUCTION
The worldwide development of bromethalin has been an 
expensive and lengthy process lasting over a decade. It has 
involved the dedicated work of people from a variety of 
disciplines including chemists, biologists, toxicologists, 
formulation scientists, regulatory specialists, and marketers.
The search for a novel rodenticide with a mode of action 
different from anticoagulants began in the mid-1970's when 
leads from a fungicide screening program at Lilly Research 
Laboratories indicated the rodenticidal potential of a group of 
compounds classified as diphenylamines (Dreikorn and 
O'Doherty 1984). After several years of screening and struc-
ture-activity relation tests, bromethalin was identified as the 
compound with the greatest biological potential. At the 1979 
British Crop Protection Conference, Dreikorn (1979) pre-
sented the first biological results from laboratory tests with 
white rats and mice. Biological and toxicological testing 
continued at Lilly until sufficient data were assembled to 
submit an application for an Experimental Use Permit (EUP). 
In 1980, the EUP was issued by the Environmental Protection 
Agency (EPA) and a field trial program was initiated in 
conjunction with the Center for Environmental Research at 
Bowling Green State University. By the end of 1981, 17 
successful field trials in Norway rat and house mouse infested 
sites were completed and the EPA granted bromethalin 
registration for use in and around buildings in 1982.
Marketing rights were subsequently licensed by Eli Lilly 
to Ralston Purina and Velsicol in the United States and Ciba-
Geigy for all countries outside the United States. Ciba-Geigy 
initiated development in 1984 under the tradename DORAT-
ID1*. During the following year, ASSAULT1* was introduced 
into U.S. markets by Ralston Purina, and Velsicol followed
in 1986 with the introduction of Vengeance. Over the past 4 
years, Ciba-Geigy has focused on formulation development 
of grain-based baits and a bonded weather-resistant block, as 
well as conducting several additional toxicology studies 
required to meet European registration requirements. This 
work is now coming to an end and registration was initiated 
in 1988 in selected European countries.
It is the intent of this paper to review the status of 
bromethalin and to discuss efficacy and toxicology studies 
conducted outside the United States over the past 4 years.
REVIEW OF SELECTED BROMETHALIN TOXICO-
LOGICAL PROPERTIES
Toxicological aspects of bromethalin have been previ-
ously reviewed by Jackson et al. (1982), Spaulding et al. 
(1985), and Spaulding (1987). This brief review of toxico-
logical data focuses on acute and subchronic toxicity and 
aspects related to pharmacodynamics, pharmacokinetics, 
and metabolism. 
Acute Toxicitv
Bromethalin acute LD50 values for the active ingredient 
in target and non-target species range from 1.8 mg/kg (cat) to 
13.0 mg/kg (rabbit). LD50's of 2.3,6.7, and 6.6 mg/kg have 
been determined for the Norway rat, house mouse, and roof 
rat, respectively. The acute LD50 of the 0.01% finished bait 
is >2000 mg/kg.
Subchronic Toxicitv
Subchronic and chronic toxicity tests with pesticides are 
designed to assess the toxicity and human carcinogenicity 
risk to humans in prolonged exposure situations. The EPA 
required only 14-day feeding studies with bromethalin to
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support registration in the United States; however, 90-day 
feeding studies were required for registration in several 
European countries. While these 90-day tests are certainly 
applicable in the case of herbicides and insecticides applied 
to crops, the scientific value of these studies with rodenticides 
is questionable due to completely different use patterns. 
Rodenticides are applied in discrete locations in relatively 
small quantities; therefore, the potential for human exposure 
or food contamination is minimal.
In several early toxicity studies with bromethalin (van 
Lieretal. 1980, van Lier and Ottosen 1981), histopathologi-
cal signs of toxicity indicated vacuolation of the white matter 
of the brain and spinal cord, which appeared as a spongy 
degeneration. To determine whether this spongy degenera-
tion was a reversible phenomenon, two 14-day subchronic 
reversibility studies were undertaken (van Lier et al. 1980, 
van Lier and Cherry 1988). Rats were dosed with 0,0.5,2 or 
8 ppm bromethalin in one study and 0, 1, 3, and 5 ppm 
bromethalin in a second study. Brain, spinal cord and sciatic 
nerve tissues were examined histologically over an 8-week 
recovery period. Behavior and motor coordination were 
measured in the second study using a rotorod. All rats given 
8 ppm bromethalin died during treatment or were killed when 
moribund. Leg weakness and depressed motor function were 
observed by day 7 in rats given 5 ppm bromethalin. Electron
and light microscopic examination of rat tissues taken at 
various times during these studies demonstrated that the 
primary lesions which occurred were spongy degeneration of 
the CNS white matter. However, the incidence of spongy 
degeneration decreased sharply at two and four weeks post-
treatment and was not evident at eight weeks posttreatment, 
demonstrating the reversibility of these lesions. Furthermore, 
histological examination of tissues revealed no evidence of 
cell necrosis.
In order to conduct 90-day subchronic toxicity studies 
with inherently toxic rodenticides, extremely low doses must 
be administered in order to keep test animals alive throughout 
the 90-day test period. These doses were established for 
bromethalin subchronic studies by conducting 4-week pilot 
studies first with rats and dogs. In definitive studies (Ciba-
Geigy, unpubl. rept.), rats and dogs were dosed with 0,5,25, 
125, and 200 (dogs only) mcg/kg bromethalin daily over 90 
days.Lesions were evident only atdosesof > 125 mcg/kgand 
were characterized by the typical spongy degeneration of 
CNS white matter seen in the 14-day studies. Even under 
extended subchronic exposure, a "no observable effect level" 
(NOEL) of 25 mcg/kg was demonstrated in rats and dogs.
Pharmacodvnamics/Pharmacokinetics/Metabolism
Several studies have been conducted to investigate the 
mechanism of action, metabolism, tissue distribution and 
excretion of bromethalin in laboratory rats. Van Lier and 
Cherry (1988) recently described the mechanism of action of 
bromethalin. Based upon their results from several mechanis-
tic studies, the following mode of bromethalin toxicity is 
proposed. Upon ingestion, bromethalin is metabolized to 
desmethyl   bromethalin   which   uncouples   oxidative
phosphorylation in the mitochondria. The sodium/potassium 
gradient normally maintained by sodium-potassium ATPase 
is weakened, and fluid builds up in the cell. While most 
tissues and organs can expand slightly to accommodate this 
effect, a fluid build-up inside the central nervous system leads
to increased pressure on nerve axons. Demyelination occurs 
and nerve impulse transmission is reduced. In the lethally 
intoxicated animal, this leads to inadequate transmission to 
respiratory centers with ultimate respiratory arrest and death. 
The entire process is dose-dependent and death generally 
occurs from 12-72 hours following ingestion.
Studies with radio-labelled bromethalin have provided 
insights into the pharmacokinetic and metabolic aspects of 
bromethalin (van Lier and Ottosen 1981, van Lier and Cherry 
1988). One study using radio-labeled bromethalin resulted 
in disappearance of radiocarbon from plasma at a rate which 
indicated a half-life of about 135 hours. Other studies using 
radio-labeled bromethalin indicated excretion is primarily 
through the feces and that bromethalin is absorbed after oral 
administration and distributed primarily to the fat, liver, 
gastrointestinal tract, adrenals, ovaries and thyroid tissues.
LABORATORY EFFICACY STUDIES
Laboratory choice tests were conducted with a variety of 
0.01% bromethalin grain-based and weather-resistant 
bonded block formulations using anticoagulant susceptible 
and resistant Rattus norvegicus and Mus musculus. The 
studies were conducted at the following international re-
search institutes:
1. Ciba-Geigy Agricultural Research Centre - Switzerland
2. INRA, Laboratoire de la Faune Sauvage - France
3. Danish Pest Infestation Laboratory - Denmark
4. MAFF Tollworth Laboratories -U.K. Ministry of Agricul-
ture, Fisheries and Food
Data from the Ciba-Geigy Agricultural Research Centre 
have been published in part by Spaulding (1987).
A pooled data summary of choice tests with bromethalin 
grain-based formulations using individually-caged wild R. 
norvegicus is presented in Table 1. A total of 422 rats were 
used in 27 different tests. Formulations included 0.01% 
bromethalin whole oats and wheat, cracked or pinhead oats, 
or oat flakes. Average percent mortality of 97% (range 94-
100%) was achieved within an average of 2.3 days (range 1.4-
4.0 days) following ingestion of bromethalin baits. Formula-
tions containing bromethalin were consumed an average of 
48% (range 30-71%) of the time compared to untreated 
alternative diets.
A pooled data summary of choice tests with bromethalin 
weather-resistant block formulations using individually-
caged R. norvegicus is presented in Table 2. A total of 145 rats 
were used in 11 different tests. Formulations consisted of 
whole wheat or oats or cracked maize impregnated with 
0.01% bromethalin and bonded together in a patented proc-
ess. Laboratory tests have shown this formulation to be highly 
palatable to rats and resistant to moisture and heat. Average 
percent mortality of 96% (range 83-100%) was achieved 
within an average of 3.5 days (2.1-4.6 days) following
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Table 1: Choice tests with 0.01% Bromethalin Grain 
Formulations Against Individually-Caged R. norvegicus.
ingestion of the bromethalin blocks. Blocks containing brom-
ethalin were consumed an average of 60% (range 47-82%) of 
the time compared to untreated alternative blocks.
A pooled data summary of choice tests with bromethalin 
grain-based formulations using family groups (8-20 mice/ 
group) of wild M- musculus is presented in Table 3. Formu-
lations included 0.01% bromethalin canary seed, cracked 
oats, or oat flakes. A total of 326 mice were used in 20 
different tests. Average percent mortality of 97% (range 92-
100%) was achieved within an average of 2.3 days (range 1.5-
2.8 days) following ingestion of bromethalin baits. Formula-
tions containing bromethalin were consumed an average of 
59% (range 37-88%) of the time compared to untreated 
alternative diets.
A pooled data summary of laboratory tests with brom-
ethalin grain-based formulations using anticoagulant-
resistant R. norvegicus and M- musculus is presented in Table 
4. A total of 170 resistant rodents were tested at research 
institutes in France, England, and the United States. The R.
Table 2. Choice Tests with 0.01% Bromethalin Weather-
Resistant Block Formulations Against Individually-Caged 
R. norvegicus.
Table 3. Choice Tests with 0.01 % Bromethalin Grain Formu-
lations Against Family Groups of M- musculus
'Source:    1. Ciba-Geigy Unpublished Report
2. Grolleau. 1987. Proceedings Rome EPPO/FA Conference
on Rodents
3. Lund. 1986. Unpublished Data
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Table 4. Laboratory Tests with 0.01% Bromethalin Grain 
Formulations Using Anticoagulant-Resistant R. norvegicus 
(RN) and M- musculus (MM). 
                                          N      Bromethalin   Mort-     Days to 
Country*** Species   (# Tests) Consumption    ality        Death
norvegicus tested in France were determined resistant to 
bromadiolone. Average percent mortality of 92% (range 80-
100%) was achieved within an average of 2.9 days (1.6-4.0 
days) following ingestion of bromethalin baits. Formulations 
containing bromethalin were consumed an average of 45% 
(range 30-63 %) of the time compared to untreated alternative 
diets.
FIELD EFFICACY TRIALS
Seventeen (17) field trials were completed with 0.005% 
bromethalin EPA baits in primarily rural sites such as live-
stock barns, poultry farms and storage buildings in 5 geo-
graphically different regions of the United States (Jackson et 
al. 1982, Spaulding et al. 1985). Average percent reduction 
in rodent activity in these trials ranged from 90-98% in 8 R. 
norvegicus tests and from 85-99% in 9 M-musculus tests. 
Bromethalin treatment periods ranged from 7-30 days and 
there were no incidents of primary or secondary poisoning to 
non-target species during the trial program.
Field trials completed outside the United States are 
summarized in Tables 5 and 6 for R. norvegicus and M-
musculus respectively. Nine (9) R. norvegicus infestations 
were treated with 0.005% or 0.01% bromethalin grain baits 
in Switzerland, Denmark, England, Ireland and Brazil. 
Average percent reduction in census feed consumption 
ranged from 83 to 100% after 3 to 14 days of exposure to 
bromethalin baits. Four (4) M. musculus populations were 
treated with 0.01% bromethalin grain baits in France and 
Switzerland. Average percent reduction in census feed con-
sumption ranged from 98 to 100% with 3 to 16 days of 
exposure to bromethalin baits. One hundred-fifty (150) 
mouse carcasses were recovered during the trial in France. 
There were no incidents of primary or secondary poisoning 
to non-target species in these trials.
Table 5. Field Trials with 0.005% and 0.01% Bromethalin 
Grain Formulations Against Infestations of R. norvegicus.
Table 6. Field Trials with 0.01% Bromethalin Grain Formu-
lations Against Infestations of M-musculus.
RODENTICIDE PEN TESTING 
Test Procedure
An indoor pen test system was established so that indirect 
comparisons of rodenticides could be made under similar 
conditions. Indoor pens measuring 4x2x2 (8 m2) were con-
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structed on a concrete base with stainless steel wire mesh. The 
bottom of the pens was covered with approximately 10 cm of 
saw dust and abundant harborage was provided in the form of 
overturned plastic containers. Wild male and female Norway rats 
were introduced into the pen and provided standard laboratory 
diet and water ad libitum. Rodents were allowed to acclimate 
for 10-12 weeks before testing and obviously dominant or 
submissive animals were removed. Twelve (12) bait trays 
containing either 2 kg of rodenticide or untreated grain were 
distributed throughout the pen. The position of the bait trays was 
alternated daily and consumption was measured. Dead animals 
were removed when located. A diagram of the testing facility is 
shown in Figure 1.
Fig. 3. Efficacy of 0.005% Bromadiolone oat baits in a pen trial with 92 
wild Norway rats.
Comparative Rodenticide Tests
The objective of these tests was to compare the palata-
bility and efficacy of bromethalin with leading second-
generation anticoagulants under controlled conditions.
Results from tests with 0.01% bromethalin and C.005% 
bromadiolone oat formulations and 0.005% brodifacoum 
commercial pelleted formulations are presented in Figures 2, 
3, and 4, respectively.
Fig. 2. Efficacy of 0.01% Bromethalin oat baits in a pen trial with 125 
Norway rats.
Fig. 4. Efficacy of 0.005% Brodifacoum pellets in a pen trial with  94 
Norway rats.
A total of 836 g of untreated oats and 973 g of 0.01% 
bromethalin oat baits were consumed by 125 R. norvegicus 
in the bromethalin test pen over 6 days. This corresponds to 
28.7 g of bromethalin bait/kg rat and 24.7 g untreated grain/ 
kg rat. Complete mortality was achieved by the sixth day of 
baiting (x = 2.4 days).
In the bromadiolone test pen, a total of 1722 g of 
untreated oats and 1628 g of 0.005% bromadiolone oat baits 
were consumed by 92 R. norvegicus over 10 days. This 
corresponds to 99.1 g of bromadiolone bait/kg rat and 93.7 g 
untreated grain/kg rat. Complete mortality was achieved by 
the 10th day of baiting (x = 5.5 days).
A total of 6615 g of untreated grain and 1442 g of 0.005% 
brodifacoum pellets were consumed by 94 R. norvegicus 
over the 10-day test period. This corresponds to 60.1 g of 
brodifacoum bait/kg rat and 275.6 g of untreated grain/kg rat. 
Incomplete mortality of 83% (78/94) was achieved after 10 
days of baiting. Rats which survived after 6 days fed almost 
exclusively on untreated grains rather than brodifacoum 
pellets.
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Fig. 1. Diagram of rodenticide test pens.
Results from these tests illustrate differences between 
the two second-generation anticoagulants and bromethalin 
based upon their respective modes of action and formulation 
types. Rats continued to feed on the two anticoagulants over 
the 10 day test period resulting in at least 2 to 3 times more 
anticoagulant bait consumption and 3 to 11 times more 
untreated grain consumption when compared to results from 
the bromethalin test pen. Feed consumption in the brom-
ethalin pen virtually stopped after 4 days, indicative of the 
efficiency of bromethalin baiting under semi-natural condi-
tions. Dead rodents were rapidly observed within 24 hours 
after baiting with bromethalin and complete mortality was 
achieved by the 6th day as compared to 10 days with 
bromadiolone. Untreated grain was preferred over pelleted 
brodifacoum formulations leading to incomplete mortality 
with this product under these experimental conditions.
Overall, these results illustrate the quick kill and effi-
ciency possible when utilizing bromethalin as an alternative 
to anticoagulant rodenticides for controlling Norway rat 
infestations.
CONCLUSIONS
The diphenylamine rodenticide bromethalin has been 
thoroughly researched over the past decade and commercial 
formulations have been safely used in and around buildings 
in the United States over the past 3 years. International 
development work has shown bromethalin to be effective 
against susceptible and anticoagulant-resistant rodents. Data 
required for European registrations are nearly complete and 
will be submitted to authorities in selected countries through-
out 1988. Bromethalin's quick kill and stop-feed action make 
this rodenticide a highly efficient alternative to anticoagu-
lants.
ACKNOWLEDGMENTS
The authors would like to thank G. Grolleau (INRA, 
France); M. Lund (PPIL, Denmark); and J. Greaves (Here-
ford, England) for their generosity in allowing us to use their 
unpublished data. We would also like to thank Mr. P. Bula 
from the Ciba-Geigy Agricultural Research Centre in St. 
Aubin, Switzerland, for his assistance in conducting labora-
tory and field tests.
LITERATURE CITED
CARVALHO, C.N. and F.A. MELLO. 1985. Field trial with
a new rodenticide: bromethalin. Biologico 51(4): 334-
336.
DREIKORN, B.A., G.O.P. O'DOHERTY, A.J. CLINTON, 
and K.E. KRAMER. 1979. EL-614, a novel new acute 
rodenticide. Proceedings British Crop Protection Conf.: 
491-498.
DREIKORN, B.A. and G.O.P. O'DOHERTY. 1984. The 
discovery and development of bromethalin, an acute 
rodenticide with a unique mode of action. In: ACS 
Symposium Series #255. Pesticide Synthesis Through 
Rational Approaches, P.S. Magee, G.K. Kahn, J.J. 
Menn (Eds.). American Chemical Society .Washington, 
D.C. pp. 45-63.
CHERRY, L.D., M.D. GUNNOE, and R.B.L. VAN LIER. 
1982. The metabolism of bromethalin and its effects on 
oxidative phosphorylation and cerebrospinal fluid pres-
sure. The Toxicologist 2(1): 108.
G. GROLLEAU. 1987. Susceptibility of 3 commensal rodent 
species to bromethalin under laboratory conditions. Pro-
ceedings Rome EPPO/FAO Conference on Rodents (in 
press).
JACKSON, W.B., S.R. SPAULDING, R.B.L. VAN LIER, 
and B.A. DREIKORN. 1982. Bromethalin - apromising 
new rodenticide. Proceedings 10th Vertebrate Pest 
Conference, R.E. Marsh (ed.). Monterey, California, pp. 
10-16.
MEEHAN, A.P. 1983. Some properties of bromethalin, a 
new rodenticide. 6th Br. Pest Control Ass.Conf., Cam-
bridge. Sept.7-10. Session 5. Paper 11. 16 pp.
SPAULDING, S.R., R.B.L. VAN LIER, and M.E. TAR-
RANT. 1982. Toxicity and efficacy of bromethalin. 
Acta Zoologica Fennica 173: 171-172.
SPAULDING, S.R. 1987. Bromethalin - an alternative to 
anticoagulants. BCPC Mono.No.37 Stored Products 
Pest Control: 137-147.
VAN LIER, R.B.L., L.D. OTTOSEN, G.K. HANASONO, 
and J.L. CARTER. 1980. Studies on the toxicity of EL-
614, a new rodenticide. Presentation 19th Annual Meet-
ing of the Society of Toxicology.
VAN LIER, R.B.L., and L.D. OTTOSEN. 1981. Studies on 
the mechanism of toxicity of bromethalin, a new roden-
ticide. The Toxicologist 1(1):114.
VAN LIER, R.B.L. and L.D. CHERRY. 1988. The toxicity 
and mechanism of action of bromethalin: a new single-
feeding rodenticide. Fundamentals of Applied Toxicol-
ogy (submitted for publication November 1987).
69

